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Abstract27
We study the epidemiology, molecular basis, clinical risk factors and outcome involved28
in the clonal dissemination of VIM-1-producing Klebsiella pneumoniae in the hospital29
setting.30
All patients infected/colonized by carbapenem non-susceptible K. pneumoniae31
(CNSKP) in 2009 were included. Molecular epidemiology was studied by Pulsed Field32
Gel Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST). Antibiotic33
resistance genes were analyzed by PCR and sequencing. Plasmids were studied by34
PFGE with S1 nuclease digestion and by the incompatibility group by a PCR-based35
replicon typing scheme. Risk factors associated with CNSKP colonization/infection36
were assessed by an observational case-control study.37
All 55 patients studied were infected (n=28) or colonized (n=27) by VIM-1-producing38
K. pneumoniae. All but one acquired isolates of a single clone (PFGE C1, ST15), while39
another clone (PFGE C2, ST340) was detected in four patients. C1 isolates also40
produced the new ESBL SHV-134. blaVIM-1 was carried into a class 1 integron and an41
untypeable plasmid of ~ 50 bp. The number of days receiving mechanical ventilation,42
the use of parenteral nutrition, previous treatment with linezolid, and treatment with43
third generation cephalosporins for more than 7 days were detected as independent risk44
factors for CNSKP acquisition.45
VIM-1 producing K. pneumoniae ST15 clone has a high capacity to spread among ICU46
patients with severe underlying conditions. A high rate of associated mortality and great47
difficulty in controlling the spread of this clone, without permanent behavioural changes48






Carbapenemases hydrolyse all beta-lactam antibiotics including carbapenems54
(5,19,33,37) and their high potential for rapid, wide dissemination constitutes a major55
clinical and public health threat (5,18,19,24,26-28,37). Class B carbapenemases include56
metallo-β-lactamases (MBLs) such as VIM, IMP and NDM-1 (19,24). Acquired MBLs 57
are increasingly reported from Enterobacteriaceae (5,9,14,10,24,35,37).58
Klebsiella pneumoniae is a major cause of nosocomial infections, particularly in59
intensive care units (ICUs), representing a relevant potential clinical risk. During the60
last decade, VIM-type MBLs have spread in K. pneumoniae (2,21,31,32,35,38) and61
outbreaks of such strains have been reported (2,21,32).62
In Spain, VIM-1-producing Enterobacteriaceae have been described associated63
to single cases, to small outbreaks (6,31,36), or to polyclonal spread affecting different64
bacterial species (25,35).65
This study describes an extensive nosocomial outbreak caused by a clonal66
multidrug-resistant strain of K. pneumoniae producing VIM-1. Our aims were to assess67
the epidemiology, molecular basis, clinical risk factors and outcomes involved in the68




Study design and bacterial isolates73
During 2009, an increase in the isolation of carbapenems-non-susceptible K.74
pneumoniae (CNSKP) isolates was noted in the University Hospital Puerta de Hierro75
Majadahonda (UHPHM) in Madrid, Spain. This observation prompted the present76
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investigation. UHPHM is a tertiary care hospital, with 613 inpatient beds, 52 intensive77
care beds, and over 17,000 hospital admissions per year.78
All the patients infected and/or colonized by CNSKP isolates between January79
2009 and December 2009 were included in this study. An infected case caused by80
CNSKP was defined according to CDC criteria (17); a colonized case was defined as a81
patient carrying CNSKP without clinical evidence of infection.82
83
Bacterial identification and susceptibility testing84
Species identification and antibiotic susceptibility testing were performed by85
broth microdilution (MicroScan, Siemens Healthcare Diagnostics, Deerfield, IL) and by86
E-test (AB-Biodisk, Solna, Sweden). Susceptibility results were interpreted according to87
Clinical and Laboratory Standards Institute (CLSI) guidelines (8). Antibiotic-88
susceptible E. coli ATCC 25922 and carbapenems-resistant E. coli MN4 (30) were used89
as quality control strains. Tigecycline susceptibility was determined by the E-test and90
interpreted according to European Committee on Antimicrobial Susceptibility Testing91
(EUCAST) guidelines (13).92
Carbapenems-non-susceptibility was considered as resistance or intermediate93
susceptibility to one of more of the three carbapenem antibiotics tested: imipenem,94
meropenem and ertapenem.95
Modified Hodge test using an imipenem disk was carried out; imipenem96





The genetic relatedness between the K. pneumoniae isolates was determined by101
pulsed-field gel electrophoresis (PFGE) after total chromosomal DNA digestion with102
XbaI (30).103
K. pneumoniae isolates representing the different PFGE clusters were further104




Antibiotic resistance mechanisms and class 1 integron characterization109
Standard PCR conditions were used to amplify genes coding for carbapenemases110
(blaKPC, blaVIM, blaIMP, blaNDM), extended spectrum β-lactamases (ESBL) (blaTEM,111
blaSHV, and blaCTX-M), and plasmid-mediated AmpC (blaCMY, blaFOX, blaMOX, blaDHA,112
blaEBC blaACC). Aminoglycoside acetylase resistance genes (aac(3)-IIa, aac(6')-Ib) and113
16S RNA methylases (armA, rmtA, rmtB) were also screened (15,30).114
Class 1 integron structures, the integrase gene intI1 and the variable regions, as115
well as the linkage of blaSHV-134 allele with IS26 were screened by PCR amplification116
and DNA sequencing (12,34).117
In addition, the entire sequences of the ompK35 and ompK36 genes were118
analyzed by PCR and DNA sequencing in four isolates representing the two CNSKP119
clones detected (20).120
121
Conjugation assay and plasmid characterization122
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Conjugation experiments were performed with four donor K. pneumoniae123
clinical isolates, previously selected according to PFGE results, using the kanamycin-124
azide resistant E. coli Hb101 as a recipient. Putative transconjugants were selected on125
Mueller-Hinton agar plates containing kanamycin (100 μg/ml), azide (160 μg/ml), and 126
cefotaxime (4 μg/ml). 127
Plasmids were classified according to their incompatibility group by a PCR-128
based replicon-typing scheme (3). PFGE with S1 nuclease digestion of whole genomic129
DNA (S1-PFGE) was used to detect plasmids as previously described (16).130
131
Case-control clinical study132
A retrospective observational case-control study was conducted among patients133
admitted to the medical (MICU) or surgical ICU (SICU) between January and134
December 2009.135
All the ICUs patients were screened by rectal cultures at least once a week until136
hospital discharge. A case was defined as a patient admitted to either of the two ICUs137
during the study period who presented infection or colonization by VIM-1-producing K.138
pneumoniae after 48 hours’ admission in the ICU. Control patients were randomly139
selected from monthly lists of patients admitted to the ICUs during the same period as140
the patient case, with an ICU stay greater than 48 hours, and with no evidence of141
CNSKP infection or colonization in any of the clinical or surveillance samples taken.142
Death associated to the infection was defined as persistence of signs and143
symptoms of infection by VIM-1-producing K. pneumoniae at the time of death, or144
death occurring within 14 days after the diagnosis of VIM-1-producing K. pneumoniae145
infection without evidence of another obvious cause.146
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Information about the potential clinical risk factors (underlying medical147
conditions including, as well as surgical procedures, use and duration of invasive148
devices, and type and duration of antimicrobial treatment) were recorded. In addition149
Charlson modified index (1,7) and Apache II scores were also recorded on admission to150
the ICU (22).151
The periods used for the determination of risk factors were from admission until152
the date of colonization or infection by VIM-1-producing K. pneumoniae (for cases) and153
from admission to discharge from the ICU (for controls).154
155
Statistical analysis156
Comparison of discrete variables was performed by univariate logistic157
regression. Continuous variables were compared by student’s t test or Wilcoxon rank158
sum (Mann-Whitney) test, as appropriate. Two multivariate logistic regression models159
were developed with the purpose of determining the potential independent risk factors160
associated with VIM-1-producing K. pneumoniae infection/colonization, adjusted by161
APACHE II score: a general model and a model that only included the use of antibiotics162
as risk factors. On the basis of a complete model, which included all the risk factors that163
showed a value p<0.20 in the univariate analysis, the final model was built using the164
maximum likelihood method using a backward strategy of selecting variables. Adjusted165
Odds ratios (ORs) were calculated including their 95% confidence intervals. Two-tailed166
test were used for all analyses. p values <0.05 were considered statistically significant.167





During 2009, CNSKP isolates were obtained from clinical samples of 55 patients,172
admitted in either the SICU (n=36, 65.5%) or the MICU (n=19, 34.5%). Of the 55173
patients, 28 (50.9%) were infected by CNSKP, while 27 (49.1%) had no clinical174
evidence of infection and were considered colonized. The incidence of new cases in the175
SICU was significantly higher than in the MICU (16.7 vs. 6.1 cases/1,000 patient-days)176
(RR: 2.7, 95% CI: 1.6-4.7; p<0.001). Thirty-five (63.6%) patients were male. Twenty-177
one (38.2%) were >65 years old, and 34 (61.8%) were >18 and ≤65 years old. The 178
median number of days of MICU/SICU stay was 36 days (range: 3-101 days).179
Clinical characteristics, treatment and outcome of the patients infected by180
CNSKP are detailed in Table 1. The most prevalent infections diagnosed were181
pneumonia and catheter-associated bacteremia with seven cases (25%) each one. Of the182
27 patients colonized, CNSKP was recovered from exudates of the rectum (22 cases;183
78.6%), trachea (3 cases; 11.1%), urethra (1 case; 3.7%), and bladder catheter (1 case;184
3.7%).185
Of the 55 patients studied, 45 (81.8%) had previous underlying conditions and186
25 of them (55.6%) had more than one. The most prevalent underlying diseases were187
neoplasia (13 cases, 25.5%), immunosuppression due to solid organ transplantation (12188
cases, 21.8%) and heart diseases (21 cases, 38.2%).189
Thirteen (46.4%) infected patients and 11 (40.7%) colonized patients died, all of190
them with severe underlying diseases.191
Twenty-two of the 28 (78.6%) infected patients were treated with antibiotics192
active against CNSKP, mainly tigecycline in monotherapy (9 cases; 32.1%), or193
combined with colistin (11 cases; 39.3%) (Table 1). Of the remaining 6 infected194
patients, 2 were treated with meropenem or ertapenem because their isolates MICs for195
both antibiotics were 1 µg/ml and interpreted as susceptible according to previous CLSI196
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criteria (ertapenem ≤ 2 μg/ml and meropenem ≤ 4 μg/ml, document M100-S20), 2 did 197
not receive treatment due to early death, and the clinical condition of 2 patients198
improved after central venous catheter or bladder catheter removal (Table 1).199
Nineteen of the 28 patients infected (67.9%) received adjuvant treatment, mainly200
change or removal of central venous catheter (14 patients) (Table 1).201
202
Susceptibility testing of CNSKP isolates203
During the study period, 335 CNSKP isolates were recovered from different204
samples of the 55 patients studied. All of them were resistant to ampicillin,205
amoxicillin/clavulanic acid, cefoxitin, cefotaxime, ceftazidime, piperacillin/tazobactam,206
gentamicin, tobramycin, ciprofloxacin and cotrimoxazole; 36% were susceptible to207
amikacin. The MICs for tigecycline ranged from 0.25 μg/ml to 4 μg/ml (MIC50=0.5208
μg/ml, MIC90=1 μg/ml). All isolates were susceptible to colistin (MICs < 2 μg/ml). 209
Imipenem, meropenem and ertapenem MICs ranged from 1 to > 8 μg/ml (MIC50210
and MIC90 >8 μg/ml in all cases). The modified Hodge the imipenem/imipenem-EDTA 211
E-test strips were positive in all CNSKP K. pneumoniae isolates.212
213
Molecular epidemiology214
In total, 99 representative CNSKP isolates were subjected to further molecular215
epidemiology studies. PFGE results revealed two well-defined clusters. Cluster 1 (C1)216
was predominant in both infected (n=27) and colonized (n=27) patients, while cluster 2217
(C2) was only isolated from four patients, although only one was infected; the three218
patients colonized by isolates of C2 cluster were also infected (n=1) or colonized (n=2)219
by isolates of C1 cluster.220
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According to the minor banding patterns differences found, C1 cluster could be221
subdivided into four subtypes, C1A to C1D; also in the C2 cluster, two subtypes were222
identified, C2A and C2B (Figure 2). By MLST analysis, clusters C1 and C2 were223
identified as ST15 (six isolates tested; three of subtype C1A, and one of each C1B, C1C224
and C1D) and ST340 (three isolates tested; two of subtype C2A and one of C2B),225
respectively (Figure 1). This is the first description of VIM-1-producing K. pneumoniae226
ST15, MLST type previously associated to CTX-M-15-producing epidemic clones in227
Hungary and Denmark (11,29). The ST340 is a single-locus variant of the widely228
disseminated KPC-producing ST258 strain (18).229
230
Antibiotic resistance genes and class 1 integron characterization231
blaVIM-1 was identified in both C1/ST15 and C2/ST340 clones. blaVIM-1 was232
carried into a class 1 integron in the following cassette combination: intI1 (integrase233
gene) - blaVIM-1 - aac(6’)-Ib (tobramycin-resistance gene, also called aacA4 ) - dhfrII234
(thrimethoprim-resistance gene) - aadA1 (streptomycin-resistance gene) - catB2235
(chloramphenicol-resistance) - qacEδ1/sul-1 (quaternary ammonium compounds-236
resistance gene/sulphonamides-resistance gene).237
C1/ST15 isolates also had the new blaSHV-134 gene codifying the ESBL SHV-238
134, (http://www.lahey.org/studies/webt.asp). blaSHV-134 has a single nucleotide change239
at position 448 (C→G) in comparison with blaSHV-12, that codes for an amino acid240
substitution at position 154 (Q→E) (GeneBank accession number HM559945). The 241
insertion sequence IS26 was detected linked 73 bp upstream of blaSHV-134, as previously242
described in the blaSHV-12 gene (12). This fact supports the idea of genetic evolution of243
blaSHV-134 from the blaSHV-12 gene.244
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The blaTEM-1 gen and the aminoglycoside resistance gene aac(3')-IIa were also245
identified in K. pneumoniae isolates representatives of both clones.246
A selected sample of four K. pneumoniae isolates representing the different247
clones (two C1/ST15 and two C2/ST340 isolates) with MICs > 8 μg/ml to imipenem, 248
meropenem and ertapenem was studied further to determine ompK35 and ompK36249
sequences. In the two C1/ST15 isolates, the DNA sequences of ompK35 and ompK36250
showed point mutations at positions 690 (G →A) and 360 (C→A), generating a TGA251
and TAA premature stop codons, respectively. In the two C2/ST340 isolates, the252
sequence of ompK35 had a point mutation at position 520 (C→T), generating a TAG253
premature stop codon, whereas no changes were detected in the ompK36 sequence.254
255
Conjugation assay and plasmid characterization256
Carbapenem-non-susceptible E. coli transconjugants were obtained from isolates257
of the C1/ST15 and C2/340 clones. All transconjugants carried a plasmid of ~ 50 kb258
that was untypeable by PCR from which positive identification of blaVIM-1 gene and259
class 1 integron were obtained (Table 2). Untypeable plasmids of a similar size were260
found in a recent study by Miro et al. (25). Previous European studies had detected261
blaVIM-1 associated to plasmids of the incompatibility groups N (32), I (35) and HI2262
(25,35).263
In addition, cefotaxime-resistant but carbapenem-susceptible transconjugants264
were also obtained from isolates of the C1/ST15 clone that were TEM-1 and SHV-134-265
producers and carried a single IncFIIA plasmid of ~ 75 kb (Table 2). Simultaneous266
production of VIM-1 and ESBLs of the SHV family has been previously described in K.267
pneumoniae (2,32,35), but this is the first report of the novel ESBL SHV-134 and VIM-268
1. blaSHV-134 being located in a conjugative IncFII plasmid other than the plasmid269
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harbouring the blaVIM-1 gene. Previous reports described the association of blaSHV-12270
with InFII plasmids (12,29).271
272
Case-control clinical study273
All the 55 patients infected and/or colonized by VIM-1-producing K.274
pneumoniae and 55 control patients were included in the study. No differences could be275
found between case and control patients regarding age, gender and frequency of surgery276
(Table 3).277
Total hospital stay was higher for cases than for controls (median stay 36 vs.7278
days; p<0.001), as well as the Apache II index (21.4 vs. 18.8; p=0.08). No significant279
differences in frequency of underlying diseases were observed between both groups,280
however, the case-fatality ratio was significantly higher for case patients than for281
control patients (45.5% vs. 30.9% respectively; p=0.003).282
In general, infection or colonization by VIM-1-producing K. pneumoniae was283
significantly associated with total previous exposure to invasive devices and lengthened284
stay in the ICU (p<0.001); in particular exposure to central and peripheral venous285
catheter, to mechanical ventilation, to nasogastric tube, to parenteral nutrition and to286
tracheotomy. Cases also received more antibiotics and for longer periods of time than287
their control counterparts (Table 3). Furthermore, use of quinolones, carbapenems,288
piperacillin-tazobactan, linezolid and third generation cephalosporins for more than 7289
days were associated to a greater risk of acquiring CNCKP (Table 3). The main290
independents risk factors identified by the general multivariate model were the number291
of days receiving mechanical ventilation and the use of parenteral nutrition; previous292
treatment with linezolid and third generation cephalosporins for more than 7 days were293
identified as risk factors by the antimicrobial use model (Table 4).294
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Taking in account that the size of this observational study precludes the295
identification of several independent factors, which would otherwise be interrelated, the296
factors that were identified indicated a group of very sick patients who required297
intensive care for long periods of time. These factors give greater opportunities to298
acquire the bacteria, especially in an environment where intensive antibiotic treatments299
select those species resistant to many antibiotics. One of the interesting findings in this300
observational study is the independent association of a previous exposure of cases to301
linezolid. On one hand it could be signalling those patients who developed more severe302
infection and were empirically treated for gram-positive microorganisms but, on the303
other hand, lizenolid could be helping to eradicate patients’ gram positive flora thereby304
allowing colonization by resistant gram-negative bacteria.305
306
Epidemic curve and infection control measures307
The epidemic curve of patients infected by CNSKP in the two ICUs units is308
displayed in Figure 2. Almost all the MICU cases appeared in the second half of the309
year, from week 27 to year end. The dissemination of CNSKP from the SICU to the310
MICU during the summer period was linked to the fact that the MICU was closed,311
therefore MICU patients were allocated to one of the SICU modules and auxiliary312
personnel were shared with SICU patients. This circumstance allowed dissemination of313
the bacteria between the two populations indicating that contact transmission is a key314
factor for the growth of the epidemic clone.315
Infection control personnel identified all patients with VIM-1-producing K.316
pneumoniae isolates recovered from any clinical specimen according to the317
microbiology laboratory reports. In addition, active surveillance of all patients admitted318
to the ICUs was performed once a week. Patients identified as harbouring VIM-1-319
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producing K. pneumoniae were assigned to contact precautions, including single room,320
when available, or patient cohorting, and the use of gowns and gloves that were321
discarded after caring for a patient. In addition, standard precautions were reinforced for322
all patients admitted to the ICUs, including improvement of hand hygiene compliance323
through the use of alcohol rubs before and after caring for patients. The outbreak324
described here did not stop during 2010 (data not shown) but remained at a lesser325
incidence towards endemicity (incidence rate 4.4 cases/1,000 patient-days in 2010).326
Eradication of these bacteria in this vulnerable population can be very difficult to327
achieve in spite of drastic measures, such as an aggressive infection control strategy.328
In this outbreak we observed three periods without cases of infection between329
weeks 10-16, 31-33 and 36-39 (Figure 2). These periods followed both the educational330
series in the SICU on week 9, and the direct observation of the personnel and the331
requirement to comply with basic hand hygiene and contact precaution measures on332
weeks 28-29 and 36-37 for the SICU and MICU, respectively (Figure 2). This latter333
intervention is costly and could not be continued due to economic constraints. Other334
potentially effective, but costly interventions that include the cohorting of carriers and335
staff, or even closing the units and the total removal of all environmental as well as336
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M 60 SICU 3 28 Pneumonia TGC + CST 50 None Death








M 53 SICU 2 8
Intraabdomi
nal
TGC 9 None Cure












F 64 MICU 7 23 UTI TGC 11 None Death








F 54 SICU 4 23
Pneumonia,
CAB










M 61 MICU 3 28 Pneumonia TGC + CST 25 None Cure
M 43 MICU 2 31 Pneumonia TGC + CST 43 None Cure












M 43 SICU 3 18
Pneumonia,
CAB














M 54 SICU 2 21 LRTI TGC + CST 28 None Death
















M 59 SICU 6 29 Soft tissue TGC 31 None Death




M 35 SICU 0 17 CAB TGC 2 None Cure






NOTE. M, male; F, female; MICU, medical intensive care unit; SICU, surgical intensive care547
unit; AMK, amikacin; TGC, Tigecycline; CST, Colistin; CAB, catheter-associated bacteremia;548
UTI, urinary tract infection; LRTI, lower respiratory tract infection; CVC, central venous549
catheter; PVC, peripheral venous catheter; BC, bladder catheter; ET, endotracheal tube; VS,550
ventricular shunt; PD, percutaneous drainage.551
552
24
Table 2. Antibiotic susceptibility and molecular characteristics for the VIM-1-553
producing Klebsiella pneumoniae isolates K534 of clone C1/ST15 and K535 of clone554
C2/ST340, and their transconjugants TC1K534, TC2K534 and TC1K535.555
556
Antibiotics K534 TC1K534 TC2K534 K535 TCK535 E. coli
Hb101
Ampicillin >16 >16 >16 >16 >16 ≤4 
Amox/Clav >16 >16 8 >16 >16 ≤4 
Cefazolin >16 >16 > 16 > 16 >16 ≤4 
Cefoxitin >16 > 16 ≤4 > 16 16 ≤4 
Cefotaxime >64 32 4 > 64 64 ≤1 
Ceftazidime >128 128 32 > 128 64 ≤1 
Cefepime >16 8 2 >16 4 ≤1 
Aztreonam >16 ≤1 >16 ≤1 ≤1 ≤1 
Imipenem >32 4 0,12 16 4 0.12
Meropenem >32 1 0,03 4 1 0.03
Ertapenem >32 1 0,015 4 1 0.015
Piper/Taz > 64 >64 ≤8 >64 >64 ≤8 
Ciprofloxacin >2 ≤ 0.12 ≤ 0.12 >2 ≤ 0.12 ≤0.12 
Gentamicin >8 ≤ 2 >8 4 ≤2 ≤2 
Tobramicin >8 4 >8 8 4 ≤2 
Amikacin 32 ≤ 8 16 ≤ 8 ≤8 ≤8 
Modified Hodge Test pos pos neg pos pos neg
Imipenem-EDTA
synergy test
pos pos neg pos pos neg
blaVIM-1 pos pos neg pos pos -
blaSHV-134 pos neg pos neg neg -
blaTEM-1 pos neg pos pos neg -
aac (6’)-Ib pos pos neg pos pos -
aac(3')-IIa pos neg pos pos neg -
Class 1 integron pos pos neg pos pos -
PFGE profile C1 - - C2 - -
MLST ST15 - - ST340 - -









NOTE. Minimal inhibitory concentrations expressed in μg/ml 558














OR 95% IC p
Days at risk, median (range) 18(5-63) 7(3-110) 0.001
a
Apache II risk index, mean (SD) per 10
units of increment
41.0(22.9) 18.8(8.3) 1.5 0.9-2.5 0.08
Charlson Index, mean (SD) 3.2(2.2) 3.5(2.2) 0.9 0.8-1.1 0.5
Patient-specific risk factor
Chronic lung disease 1(1.8) 5(9.1) 0.2 0.03-2.2 0.1
Diabetes mellitus 7(12.8) 11(20.0) 0.6 0.2-1.6 0.3
Chronic renal insufficiency 6(10.9) 6(10.9) 1 0.3-3.3 1
Malignancy 14(25.5) 13(23.6) 1.1 0.5-2.6 0.8
Cardiovascular disease 21(38.2) 24(43.6) 0.8 0.4-1.7 0.6
Liver disease 3(5.6) 6(10.9) 0.5 0.1-2 0.3
Blood disease 3(5.5) 4(7.3) 0.7 0.2-3.5 0.7
Neurologic disease 10(18.2) 5(9.9) 2.2 0.7-7.0 0.1
Immunosuppression 12(21.8) 16(29.1) 0.7 0.3-1.7 0.3
Healthcare-associated factors
Presence of CVC, days
0-7 6(10.9) 34(61.8) 1
8-21 29(52.7) 16(29.1) 10.3 3.6-29.7 <0.001
>21 20(36.4) 5(9.1) 22.7 6.1-83.9 <0.001
Presence of PVC, days
0-7 14(25.5) 32(58.2) 1
>7 41(74.6) 23(41.8) 4.1 1.8-9.2 0.001
Presence of mechanical ventilation,
days
0-7 7(14.9) 34(72.3) 1
8-14 14(29.8) 8(17) 6.7 2.4-18.6 <0.001
>14 26(55.3) 5(10.6) 5.0 7.0-84.2 <0.001
Presence of nasogastric tube, days
0-7 9(19.2) 25(74.5) 1
8-14 12(25.5) 9(19.2) 4.4 1.6-12.3 0.004
>14 26(55.3) 3(6.4) 5.0 6.5-74.2 <0.001
Tracheostomy 31(66) 9(19.2) 7.0 3.0-16.5 <0.001
Parenteral nutrition 33(70.2) 16(34) 4.1 2.4-12.6 <0.001
26
Total invasive devices, mean 5.2(1) 3.6(1.4) 2.8 1.9-4.1 <0.001




Total antimicrobial, mean (SD) 5.0(2.3) 2.9(2.4) 1.4 1.2-1.7 <0.001
Total antimicrobial, days
0-14 20(36.4) 40(72.7) 1
15-21 15(27.3) 8(14.6) 3.8 1.4-10.3 0.01
>21 20(36.4) 7(12.7) 5.7 2.1-15.8 0.001
>7 days third-generation
cephalosporins
15(27.8) 4(7.3) 4.8 1.5-15.5 0.009
Use of antimicrobial
Quinolones 46(83.6) 30(54.6) 4.6 1.8-10.4 0.001
Carbapenems 32(58.2) 15(27.3) 3.7 1.7-8.3 0.001
Piperacillin-tazobactam 24(43.6) 12(21.8) 2.8 1.2-6.4 0.016
Aminoglycosides 5(9.1) 6(10.9) 1.2 0.4-4.3 0.751
Linezolid 38 (69.1) 12 (21.8) 8.0 3.4.18.9 <0.001
565
NOTE: Data are number (%) of patients, unless otherwise indicated. CI, confidence566
interval; OR, odds ratio; SD, standard deviation; CVC, central venous catheter; PCV,567










Table 4. Potential risk factors associated with VIM-1-producing Klebsiella pneumoniae577
colonization or infection as determined by multivariate analysis.578
579
Model OR 95% IC p
General model
Presence of mechanical ventilation, days 1.2 1.1-1.3 <0.001
Use of parenteral nutrition 3.6 1.4-9.4 0.009
Model with specific antimicrobials a
Third-generation cephalosporins (>7 days) 4.2 1.1-15.3 0.032
Linezolid 7.5 3.1-18.3 <0.001
580
NOTE. CI, confidence interval; OR, odds ratio. Multivariable analyses were performed581
by logistic regression adjusted for Apache II Index.582
a The remaining risk factors included in the general model are not shown because the583





Figure 1. Dendrogram illustrating the PFGE profiles and MLST types of the two different clones of VIM-1-producing Klebsiella pneumoniae588














Figure 2. Epidemic curve of cases of infection by VIM-producing Klebsiella pneumoniae in two intensive care units.602
603
NOTE. SICU-C: Colonized patients in surgical intensive care unit. SICU-I: Infected patients in surgical intensive care604
unit. MICU-C: Colonized patients in medical intensive care unit. MICU-I: Infected patients in medical intensive care605
unit.606
